650
vs
D
DAX Index
650
Over the past 12 months, OpGen Inc has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +13% growth.
Stocks Performance
650 vs DAX Index
Performance Gap
650 vs DAX Index
Performance By Year
650 vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
OpGen Inc
Glance View
OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The company is headquartered in Rockville, Maryland and currently employs 99 full-time employees. The company went IPO on 2015-05-05. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Company’s product portfolio includes the Curetis Unyvero System and multiplex syndromic panels, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb using next generation sequencing (NGS) technology and Artificial intelligence (AI) powered bioinformatics solutions for antibiotic response prediction, as well as the Curetis CE vitro diagnostic (IVD) marked polymerase chain reaction (PCR) based severe acute respiratory syndrome (SARS) CoV-2 test kit. The Company’s subsidiaries include Curetis GmbH and Ares Genetics GmbH.
